Introducing
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
BALOXAVIR MARBOXIL
6
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
Name: Karla Ortega
Facebook: Karla Ortega
E-mail: karlaortega04@hotmail.com
DEFINITION
Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease. It has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agent
VIDEO 1
DEFINITION
APPLICATION IN NURSING
We conducted two randomized, double-blind, controlled trials involving otherwise healthy outpatients with acute uncomplicated influenza. After a dose-ranging (10 to 40 mg) placebo-controlled trial, we undertook a placebo- and oseltamivir-controlled trial of single, weight-based doses of baloxavir (40 or 80 mg) in patients 12 to 64 years of age during the 2016-2017 season.
APPLICATION IN NURSING
VIDEO 2
ISSUE IN ECUADOR
In the phase 2 trial, the median time to alleviation of influenza symptoms was 23 to 28 hours shorter in the baloxavir groups than in the placebo group. In the phase 3 trial, the intention-to-treat infected population included 1064 patients; 88.1% of patients in each group had influenza A(H3N2) infection. The median time to alleviation of symptoms was 53.7 hours (95% confidence interval with baloxavir, as compared with 80.2 hours (95% with placebo
ISSUE IN ECUADOR
VIDEO 3
VIDEO 3
PROS -
CONS
PROS - CONS
PROS:
he time to alleviation of symptoms was similar with baloxavir and oseltamivir. Baloxavir was associated with greater reductions in viral load 1 day after initiation of the regimen than placebo or oseltamivir. Adverse events were reported in 20.7% of baloxavir recipients, 24.6% of placebo recipients, and 24.8% of oseltamivir recipients.
VIDEO 4
CONS
ingle-dose baloxavir was without evident safety concerns, was superior to placebo in alleviating influenza symptoms, and was superior to both oseltamivir and placebo in reducing the viral load 1 day after initiation of the trial regimen in patients with uncomplicated influenza.
CONCLUSION
Similar results were observed shown with oseltamivir compared with placebo. In addition, the baloxavir group had a significant decrease in viral load after 1 day of treatment compared with both placebo. Evidence for the development of decreased susceptibility to baloxavir after treatment was also observed.
CONCLUSION
VIDEO 5